AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19326141 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (F(I)O(2) = 0.21)
Number of subjects: 0
Study 19326141 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPOXIC
Number of subjects: 0
Study 17364111 — intervention group
Group type: EXPERIMENTAL
Intervention: OAS (dual-site atrial pacing with the specific pacing algorithm turned on)
Number of subjects: 25
Study 15366327 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate prolonged-release tablet formulation (60 mg)
Number of subjects: 24
Study 11443470 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol administration
Number of subjects: 40
Study 11443470 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane administration
Number of subjects: 40
Study 10186520 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently developed analysing method
Number of subjects: 0
Study 8067564 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 8
Study 8067564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3386500 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (alkalosis)
Number of subjects: 6
Study 30999884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention for 24 weeks
Number of subjects: 210
Study 30999884 — intervention group
Group type: COMPARATOR
Intervention: Standard care (waitlisted control) until receipt of patient navigator at 24 weeks
Number of subjects: 210
Study 29102016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigar Box Arthroscopy Trainer
Number of subjects: 0
Study 29102016 — intervention group
Group type: COMPARATOR
Intervention: Anatomic Knee Arthroscopy Trainer (AKAT)
Number of subjects: 0
Study 25968007 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-blocking intraocular lenses (IOLs)
Number of subjects: 1000
Study 25968007 — intervention group
Group type: COMPARATOR
Intervention: Clear intraocular lenses (IOLs)
Number of subjects: 1000
Study 23920422 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249 (5, 8, 10, or 12 mg)
Number of subjects: 125
Study 23920422 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 125
Study 23920422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 23920422 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249
Number of subjects: 125
Study 21995156 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lipohydroperoxides and glycyrrhetic acid for three days (n = 50)
Number of subjects: 100
Study 21995156 — intervention group
Group type: COMPARATOR
Intervention: Vaginal antibacterial metronidazole (500 mg) or antimycotic econazole (150 mg) for six days (n = 50)
Number of subjects: 100
Study 21995156 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lipohydroperoxides and glycyrrhetic acid
Number of subjects: 100
Study 21995156 — intervention group
Group type: COMPARATOR
Intervention: Vaginal antibacterial metronidazole or antimycotic econazole
Number of subjects: 100
Study 19337019 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG) + repaglinide
Number of subjects: 38
Study 19337019 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG) + acarbose
Number of subjects: 38
Study 16924016 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobe epilepsy surgery (amygdalo-hippocampectomy and neocortical temporal resection between 2.5 and 8 cm)
Number of subjects: 85
Study 14999200 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg/d)
Number of subjects: 225
Study 14999200 — intervention group
Group type: COMPARATOR
Intervention: captopril (50 mg 3 times/d)
Number of subjects: 225
Study 15592193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT imaging soon after exercise
Number of subjects: 52
Study 10705305 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐IL‐2 therapy (12 M IU/m2/day continuous infusion on day 1‐5, 15‐17, 29‐31, 43‐45 and 57‐59)
Number of subjects: 130
Study 10705305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no r‐IL‐2 therapy)
Number of subjects: 130
Study 9158540 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent quizzes administered at the beginning of each class (Quiz Group - QG)
Number of subjects: 0
Study 9158540 — intervention group
Group type: COMPARATOR
Intervention: No quizzes (Control Group - CG)
Number of subjects: 0
Study 9158540 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent quizzes (QG)
Number of subjects: 0
Study 1540458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Number of subjects: 31
Study 1540458 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 31
Study 1540458 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cotton swabs soaked in 4% lignocaine solution
Number of subjects: 31
Study 1540458 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 31
Study 3954967 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-poor blood components
Number of subjects: 0
Study 3954967 — intervention group
Group type: COMPARATOR
Intervention: Standard (non-leucocyte-depleted) blood components
Number of subjects: 0
Study 3954967 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-poor blood components and HLA-matched platelets
Number of subjects: 0
Study 3954967 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 29540090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME/Kegel) training, 3 times a day for 6 months
Number of subjects: 60
Study 29540090 — intervention group
Group type: COMPARATOR
Intervention: No exercises (Control group)
Number of subjects: 60
Study 27802078 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 179
Study 25451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol (15 μg bid)
Number of subjects: 841
Study 25451347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study 25451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol
Number of subjects: 841
Study 22342501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intanza(®) 15 μg intradermal vaccine
Number of subjects: 50
Study 22342501 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) Vaxigrip(®) vaccine
Number of subjects: 50
Study 20516155 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 221
Study 20516155 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 221
Study 18541078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 ml) plus ondansetron 4 mg (2 ml)
Number of subjects: 100
Study 18541078 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg (2 ml) and normal saline (2 ml)
Number of subjects: 100
Study 16183940 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate CT pulmonary angiograms
Number of subjects: 237
Study 16183940 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnostic studies)
Number of subjects: 237
Study 16183940 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up imaging
Number of subjects: 237
Study 16183940 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for thromboembolic disease
Number of subjects: 237
Study 16183940 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for follow-up imaging
Number of subjects: 237
Study 16183940 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interpretation of studies
Number of subjects: 237
Study 14569216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatments for sciatica
Number of subjects: 31
Study 10342001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 62
Study 10342001 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 62
Study 8565536 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g, 8 mmol)
Number of subjects: 32
Study 8565536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 32
Study 1759835 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (intravenous bolus injection of 3,250 anti‐Xa units) + cloxacillin (500 mg orally four times daily for 3 days)
Number of subjects: 18
Study 1759835 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (intravenous bolus injection of 3,250 anti‐Xa units) + ticarcillin (4,000 mg intravenously four times daily for 2 days)
Number of subjects: 18
Study 7058755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (800 mg/day)
Number of subjects: 182
Study 7058755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 7058755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 182
Study 29987345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy/cervicopexy (LSC‐Cx)
Number of subjects: 120
Study 29987345 — intervention group
Group type: COMPARATOR
Intervention: Anterior vaginal mesh (AVM)
Number of subjects: 120
Study 28316023 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival approach
Number of subjects: 40
Study 28316023 — intervention group
Group type: COMPARATOR
Intervention: Subciliary approach
Number of subjects: 40
Study 25681237 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D3
Number of subjects: 119
Study 25681237 — intervention group
Group type: COMPARATOR
Intervention: 50,000 IU vitamin D3
Number of subjects: 119
Study 23339040 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 116
Study 23339040 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 116
Study 23339040 — intervention group
Group type: COMPARATOR
Intervention: Historical group
Number of subjects: 116
Study 21303190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice weekly for 3 weeks, total six sessions)
Number of subjects: 90
Study 21303190 — intervention group
Group type: COMPARATOR
Intervention: Observation (routine care with weekly visits)
Number of subjects: 90
Study 21303190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 90
Study 21303190 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 90
Study 19843340 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused structural massage
Number of subjects: 399
Study 19843340 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation massage
Number of subjects: 399
Study 19843340 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 399
Study 19843340 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 399
Study 17251882 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant via endotracheal tube
Number of subjects: 152
Study 17251882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 15082488 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary vocational rehabilitation programme
Number of subjects: 65
Study 11942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in plasma malondialdehyde (SD = 0.11 microM)
Number of subjects: 58
Study 11942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in plasma 8-iso-prostaglandin F2alpha (SD = 8.88 ng/L)
Number of subjects: 58
Study 11942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in apolipoprotein B (SD = 0.27 g/L)
Number of subjects: 58
Study 11942472 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in proportion of stearic acid (18:0) in serum cholesterol esters (SD = 0.12 percent units)
Number of subjects: 58
Study 9849473 — intervention group
Group type: EXPERIMENTAL
Intervention: QUART (quadrantectomy, axillary dissection and radiotherapy)
Number of subjects: 705
Study 9849473 — intervention group
Group type: COMPARATOR
Intervention: TART (tumorectomy and axillary dissection followed by external radiotherapy and a boost with 192Ir implantation)
Number of subjects: 705
Study 7584295 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency words
Number of subjects: 0
Study 7584295 — intervention group
Group type: COMPARATOR
Intervention: High-frequency words
Number of subjects: 0
Study 7584295 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollection-based processes
Number of subjects: 0
Study 7584295 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity-based processes
Number of subjects: 0
Study 2679288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and fluorouracil (M-F) followed by leucovorin in Protocol B-13
Number of subjects: 3865
Study 2679288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice daily) in Protocol B-14
Number of subjects: 3865
Study 2679288 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Protocol B-14
Number of subjects: 3865
Study 785426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol vaccine
Number of subjects: 601
Study 785426 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virion vaccine
Number of subjects: 601
Study 785426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tween-ether ‘split’ vaccine
Number of subjects: 601
Study 785426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol vaccine (field trial)
Number of subjects: 601
Study 785426 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virion vaccine (field trial)
Number of subjects: 601
Study 6988032 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy (RM)
Number of subjects: 498
Study 6988032 — intervention group
Group type: COMPARATOR
Intervention: Simple mastectomy and postoperative radiotherapy (SM)
Number of subjects: 498
Study 28670906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet intervention
Number of subjects: 36
Study 29411724 — intervention group
Group type: EXPERIMENTAL
Intervention: LACB-7 (7-day quadruple therapy)
Number of subjects: 70
Study 29411724 — intervention group
Group type: EXPERIMENTAL
Intervention: LACB-14 (14-day quadruple therapy)
Number of subjects: 70
Study 26367239 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line chemotherapy
Number of subjects: 203
Study 26367239 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation (ASCT or allogeneic SCT)
Number of subjects: 203
Study 26367239 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 203
Study 26367239 — intervention group
Group type: COMPARATOR
Intervention: International Prognostic Index (IPI) at relapse
Number of subjects: 203
Study 26367239 — intervention group
Group type: COMPARATOR
Intervention: Transplantation
Number of subjects: 203
Study 24799480 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 204
Study 24799480 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 204
Study 22506795 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconferencing supervision (TCS; n = 32)
Number of subjects: 97
Study 22506795 — intervention group
Group type: COMPARATOR
Intervention: Standard tape-based supervision (tape; n = 32)
Number of subjects: 97
Study 22506795 — intervention group
Group type: COMPARATOR
Intervention: Workshop alone (workshop; n = 33)
Number of subjects: 97
Study 20846715 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200mg daily (escalated to 400mg)
Number of subjects: 138
Study 20846715 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20mg orally twice daily
Number of subjects: 138
Study 17641533 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg cortisol
Number of subjects: 18
Study 17641533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12607856 — intervention group
Group type: EXPERIMENTAL
Intervention: System One (chemically cured composite resin)
Number of subjects: 50
Study 12607856 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Bond (light‐cured composite resin)
Number of subjects: 50
Study 12607856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (light‐cured glass ionomer cement) with acid-etching
Number of subjects: 50
Study 12607856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (light‐cured glass ionomer cement) without acid-etching
Number of subjects: 50
Study 12607856 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivaglass Cem (self‐curing glass ionomer cement)
Number of subjects: 50
Study 10709791 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide interventions including direct action community organizing, youth development, print media, parent education, and classroom-based curriculum.
Number of subjects: 24
Study 9176721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 0
Study 9176721 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 9176721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 0
Study 9176721 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 0
Study 9176721 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 9176721 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol after Adrenaline
Number of subjects: 0
Study 9176721 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 7584010 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotrauma management principles
Number of subjects: 0
Study 7584010 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter clinical pharmacologic trials
Number of subjects: 0
Study 3100580 — intervention group
Group type: EXPERIMENTAL
Intervention: No explanation condition (minimal instructions on expected outcome)
Number of subjects: 32
Study 3100580 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanation condition (all possible sensations described and attributed to the effects of the gas)
Number of subjects: 32
Study 3100580 — intervention group
Group type: COMPARATOR
Intervention: Social phobics (both no explanation and explanation conditions)
Number of subjects: 32
Study 31959397 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported cantilever fixed partial dentures (ICFPDs)
Number of subjects: 14
Study 31959397 — intervention group
Group type: COMPARATOR
Intervention: Implant-supported conventional fixed partial dentures (IFF)
Number of subjects: 14
Study 31959397 — intervention group
Group type: COMPARATOR
Intervention: Both groups (ICFPDs and IFF)
Number of subjects: 14
Study 27492975 — intervention group
Group type: EXPERIMENTAL
Intervention: Orafti® Inulin (3 x 4g daily for 4 weeks)
Number of subjects: 44
Study 27492975 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 44
Study 26346980 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 560
Study 26346980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 560
Study 24260122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy drink containing Lactobacillus casei Shirota
Number of subjects: 60
Study 24260122 — intervention group
Group type: COMPARATOR
Intervention: Similar drink without bacteria (placebo)
Number of subjects: 60
Study 21450187 — intervention group
Group type: EXPERIMENTAL
Intervention: Res-Care Intervention
Number of subjects: 487
Study 21450187 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 487
Study 19010561 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical clips for position verification
Number of subjects: 30
Study 19010561 — intervention group
Group type: EXPERIMENTAL
Intervention: NAL protocol based on surgical clips
Number of subjects: 30
Study 19010561 — intervention group
Group type: EXPERIMENTAL
Intervention: eNAL protocol based on surgical clips
Number of subjects: 30
Study 17674599 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary catheter removal at 10:00 p.m. (Group A)
Number of subjects: 45
Study 17674599 — intervention group
Group type: COMPARATOR
Intervention: Urinary catheter removal at 7:00 a.m. (Group B)
Number of subjects: 45
Study 14692922 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium hydroxide applied for 2 minutes
Number of subjects: 60
Study 14692922 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium hydroxide applied for 1 minute combined with curettage
Number of subjects: 60
Study 11566619 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 50 mg IV
Number of subjects: 3
Study 11566619 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 150 mg IV
Number of subjects: 3
Study 11566619 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 50 mg SC (single injection)
Number of subjects: 3
Study 11566619 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 50 mg SC (six repeated injections)
Number of subjects: 3
Study 11566619 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept (various doses)
Number of subjects: 3
Study 9470156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVGG) at a dosage of 0.5 g/kg (range 0.25 to 0.73 g/kg) administered after 10.4 +/- 6.6 days of prednisone therapy
Number of subjects: 13
Study 9470156 — intervention group
Group type: COMPARATOR
Intervention: Prednisone therapy
Number of subjects: 13
Study 7801748 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study 7801748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective studies
Number of subjects: 0
Study 7801748 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective studies
Number of subjects: 0
Study 7801748 — intervention group
Group type: EXPERIMENTAL
Intervention: Random check of articles
Number of subjects: 0
Study 3616553 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 3 Hz
Number of subjects: 15
Study 3616553 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 6 Hz
Number of subjects: 15
Study 3616553 — intervention group
Group type: COMPARATOR
Intervention: Control situation (sitting for 1 h without vibration)
Number of subjects: 15
Study 30204730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment guided by visual acuity stabilization criteria (Group I)
Number of subjects: 457
Study 30204730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment guided by disease activity (Group II)
Number of subjects: 457